<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081691</url>
  </required_header>
  <id_info>
    <org_study_id>CR015574</org_study_id>
    <secondary_id>EudraCT No.: 2009-013343-11</secondary_id>
    <nct_id>NCT01081691</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 5825 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of CNTO 5825 following a
      single intravenous (IV) or subcutaneous (SC) dose administration in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study medication assigned by chance), placebo controlled, double-blind
      (neither physician or subject knows the name of the assigned study medication) study to
      assess the safety, tolerability, immune response, pharmacokinetics (what the body does to the
      drug), and pharmacodynamics (what the drug does to the body) of CNTO 5825. The study
      population will consist of 48 healthy volunteers and 16 healthy atopic volunteers. Five dose
      levels of study agent will be assessed. Participants will be required to stay at the research
      center after study agent administration for the inpatient portion of the study and then
      return for out-patient visits. Safety assessments will be performed throughout the study and
      include obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure), and
      the occurrence and severity of adverse events. Placebo (containing inactive substances only)
      or one of five dose levels of CNTO 5825 will be given. Healthy volunteers will be given a
      single IV infusion (directly into a vein) or a single dose of up to 3 injections under the
      skin. Healthy atopic volunteers will be given one dose as as an IV infusion. There will be a
      screening period of up to 4 weeks. All participants will be in the study for 17 weeks after
      dose administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CNTO 5825 by evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events in healthy volunteers.</measure>
    <time_frame>17 weeks post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effects of CNTO5825 on the body and the effects of the body on CNTO 5825 (Pharmacokinetics (PK), Pharmacodynamics (PD))</measure>
    <time_frame>17 weeks post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response (Immunogenicity) after dose with CNTO 5825</measure>
    <time_frame>17 weeks post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 5825 0.1 mg/kg single dose Intravenously (IV) or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 5825 0.3 mg/kg single dose IV or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 5825 1 mg/kg single dose IV or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 5825 3 mg/kg single dose IV or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 5825 10 mg/kg single dose IV or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 5825 For atopic patient:10 mg/kg single IV dose or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 5825 For atopic patient: 3 mg/kg single dose SC or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 5825</intervention_name>
    <description>10 mg/kg single dose IV or matching placebo</description>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 5825</intervention_name>
    <description>3 mg/kg single dose IV or matching placebo</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 5825</intervention_name>
    <description>For atopic patient:10 mg/kg single IV dose or matching placebo</description>
    <arm_group_label>006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 5825</intervention_name>
    <description>For atopic patient: 3 mg/kg single dose SC or matching placebo</description>
    <arm_group_label>007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 5825</intervention_name>
    <description>0.3 mg/kg single dose IV or matching placebo</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 5825</intervention_name>
    <description>0.1 mg/kg single dose Intravenously (IV) or matching placebo</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 5825</intervention_name>
    <description>1 mg/kg single dose IV or matching placebo</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy man or woman with no clinically significant abnormalities

          -  Body weight in the range of 50 to 100 kg inclusive

          -  Body mass index (BMI) of 18.5 to 30 kg/m2 inclusive

          -  For healthy atopic patients: history of atopic allergy

        Exclusion Criteria:

          -  Known or suspected intolerance or hypersensitivity to any biologic medication or to
             any components of the formulation used in this study

          -  Received an experimental antibody or biologic therapy within the previous 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>September 30, 2010</last_update_submitted>
  <last_update_submitted_qc>September 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr. Director, CPTM</name_title>
    <organization>Centocor</organization>
  </responsible_party>
  <keyword>CNTO 5825</keyword>
  <keyword>Safety</keyword>
  <keyword>Phase I</keyword>
  <keyword>Healthy adults</keyword>
  <keyword>Healthy Atopic adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

